COVID-19: -

Our Commitment to Client Service & Investor Communications

2020 – a transitional year

STX is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. STX’s strategy is to out-license its products for commercialisation. On 8 January, STX announced a development and commercialisation deal in China with Beijing Aosaikang Pharmaceutical Co (ASK Pharm), further validating this approach. In 2019, the FDA approved this drug for a broad indication, opening up a US market currently worth more than $1bn p.a. A US partnership deal is expected in 2020 and will be transitional for STX.

Download the full report

Request a meeting

If you'd like to be introduced to the team at Shield Therapeutics Plc, get in touch.

Request a meeting